EP2603521A4 - Molécules d'anticorps dirigées contre des isoformes oncogènes du récepteur 2 du facteur de croissance des fibroblastes et leurs utilisations - Google Patents

Molécules d'anticorps dirigées contre des isoformes oncogènes du récepteur 2 du facteur de croissance des fibroblastes et leurs utilisations

Info

Publication number
EP2603521A4
EP2603521A4 EP11817134.7A EP11817134A EP2603521A4 EP 2603521 A4 EP2603521 A4 EP 2603521A4 EP 11817134 A EP11817134 A EP 11817134A EP 2603521 A4 EP2603521 A4 EP 2603521A4
Authority
EP
European Patent Office
Prior art keywords
growth factor
factor receptor
fibroblast growth
antibody molecules
oncogenic isoforms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP11817134.7A
Other languages
German (de)
English (en)
Other versions
EP2603521A2 (fr
Inventor
Xiao-Jia Chang
Ullrich S Schwertschlag
Katherine Jane Turner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ATTOGEN Inc
Original Assignee
ATTOGEN Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ATTOGEN Inc filed Critical ATTOGEN Inc
Publication of EP2603521A2 publication Critical patent/EP2603521A2/fr
Publication of EP2603521A4 publication Critical patent/EP2603521A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
EP11817134.7A 2010-08-12 2011-08-12 Molécules d'anticorps dirigées contre des isoformes oncogènes du récepteur 2 du facteur de croissance des fibroblastes et leurs utilisations Withdrawn EP2603521A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37307210P 2010-08-12 2010-08-12
PCT/US2011/047650 WO2012021841A2 (fr) 2010-08-12 2011-08-12 Molécules d'anticorps dirigées contre des isoformes oncogènes du récepteur 2 du facteur de croissance des fibroblastes et leurs utilisations

Publications (2)

Publication Number Publication Date
EP2603521A2 EP2603521A2 (fr) 2013-06-19
EP2603521A4 true EP2603521A4 (fr) 2014-10-01

Family

ID=45568223

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11817134.7A Withdrawn EP2603521A4 (fr) 2010-08-12 2011-08-12 Molécules d'anticorps dirigées contre des isoformes oncogènes du récepteur 2 du facteur de croissance des fibroblastes et leurs utilisations

Country Status (3)

Country Link
EP (1) EP2603521A4 (fr)
CN (1) CN103201287B (fr)
WO (1) WO2012021841A2 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8663635B2 (en) 2006-03-21 2014-03-04 The Regents Of The University Of California N-cadherin: target for cancer diagnosis and therapy
US9260525B2 (en) 2008-02-04 2016-02-16 Xiao-Jia Chang Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof
KR20100132998A (ko) * 2008-04-04 2010-12-20 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 종양 성장, 혈관신생 및 전이를 차단하는 것을 목표로 하는 암에 대한 항체
RU2012153241A (ru) 2010-05-11 2014-06-20 Авео Фармасьютикалз, Инк. Антитела к fgfr2
AU2013247645B2 (en) * 2012-04-09 2019-02-14 Daiichi Sankyo Company, Limited Anti-FGFR2 antibody
WO2014089193A1 (fr) * 2012-12-04 2014-06-12 Aveo Pharmaceuticals, Inc. Anticorps anti-fgfr2
US9415118B2 (en) 2013-03-13 2016-08-16 Novartis Ag Antibody drug conjugates
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
KR102516152B1 (ko) 2013-08-01 2023-03-31 파이브 프라임 테라퓨틱스, 인크. 비푸코실화된 항-ｆｇｆｒ２ｉｉｉｂ 항체
JPWO2016171107A1 (ja) * 2015-04-20 2018-03-22 第一三共株式会社 Ｆｇｆｒ２の検出
MX2018006181A (es) * 2015-11-23 2018-09-24 Five Prime Therapeutics Inc Inhibidores de fgfr2 solos o en combinacion con agentes que estimulan el sistema inmunitario en el tratamiento contra el cancer.
CN107513106A (zh) * 2016-06-17 2017-12-26 艾托金生物医药（苏州）有限公司 抗FGFR2-IIIc单克隆抗体、杂交瘤细胞株和应用
AU2017334224A1 (en) * 2016-09-27 2019-03-21 The University Of The Highlands And Islands Antigen biomarkers
PT3624837T (pt) 2017-05-16 2025-10-01 Five Prime Therapeutics Inc Anticorpos anti-fgfr2 em combinação com agentes quimioterapêuticos no tratamento do cancro
KR102539445B1 (ko) * 2020-11-25 2023-06-05 (주)케어젠 미세먼지에 의한 세포 손상 방지 활성을 갖는 펩타이드 및 이의 용도
CN113150135B (zh) * 2021-04-14 2022-09-20 中山大学 抗新型冠状病毒受体结合区域中和抗体及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009100105A2 (fr) * 2008-02-04 2009-08-13 Attogen Inc. Inhibiteurs d'isoformes oncogènes et leurs utilisations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06000798A (es) * 2003-07-22 2006-04-07 Schering Ag Anticuerpos de rg1 y usos de los mismos.
EP1888639A1 (fr) * 2005-05-12 2008-02-20 Oncotherapy Science, Inc. Procedes pour endommager des cellules en utilisant une fonction effectrice d un anticorps anti-dsc2
WO2007011907A2 (fr) * 2005-07-19 2007-01-25 University Of Rochester Anticorps d'alpha-synucleine et techniques associees
EP2020419A1 (fr) * 2007-07-31 2009-02-04 Bayer Schering Pharma Aktiengesellschaft Fragments d'anticorps anti-ephB4
HUE035700T2 (en) * 2008-11-07 2018-05-28 Galaxy Biotech Llc Monoclonal antibodies to Fibroblast Growth Factor receptor 2

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009100105A2 (fr) * 2008-02-04 2009-08-13 Attogen Inc. Inhibiteurs d'isoformes oncogènes et leurs utilisations

Also Published As

Publication number Publication date
WO2012021841A2 (fr) 2012-02-16
WO2012021841A3 (fr) 2012-06-14
CN103201287A (zh) 2013-07-10
EP2603521A2 (fr) 2013-06-19
CN103201287B (zh) 2016-04-13

Similar Documents

Publication Publication Date Title
EP2603521A4 (fr) Molécules d'anticorps dirigées contre des isoformes oncogènes du récepteur 2 du facteur de croissance des fibroblastes et leurs utilisations
IL284368A (en) Factor ix polypeptides and methods of using them
ZA201303803B (en) Humanized antibodies to liv-1 and use of same to treat cancer
PT2918607T (pt) Moléculas de fusão de il-15 multiméricas solúveis e métodos de produção e utilização das mesmas
EP2632490A4 (fr) Nouvelles molécules se liant au récepteur egf et immunoconjugués de celles-ci
EP2419105A4 (fr) Utilisation de la transformation d'inhibiteurs de récepteur de facteur b de croissance pour supprimer une cicatrisation oculaire
EP2504031A4 (fr) Anticorps anti-il-6 et leur utilisation
LT3040424T (lt) Modifikuoti baltymai ir jų gavimo ir panaudojimo būdai
IL236738A0 (en) Human antibodies to gfra3 and methods of using them
IL235482A0 (en) Medical uses of fibroblast growth factor 21 proteins
EP2582727B8 (fr) Anticorps dirigés contre l'endoplasmine et leur utilisation
GB201218684D0 (en) Neuro-protective effects of adelostemma gracillimum and its isolated compounds
IL232950A0 (en) Antibodies against the her3 receptor that bind to its domain iii and domain iv
ZA201300174B (en) Anti-neuropilin antibodies and methods of use
IL229748A0 (en) Compounds that bind to human β1-adrenoceptor (ß1-ar) and their use in the measurement of ar-a1 autoantibodies
IL225494A0 (en) Methods of using small molecules that modulate the activity of hepatocyte growth factor (dispersion factor)
EP2603459A4 (fr) Synthèse de stannane et de deutérostannane
EP2591368A4 (fr) Procédé de détermination de la consommation d'éthanol
TWM386327U (en) Girder structure made of bamboo
HUP1100092A2 (en) Arrangement for production and using of biogas
TWM386067U (en) Structure to make the top of van higher and to reinforce the same
TWM389117U (en) Improved structure of light and convenient spur
GB201010669D0 (en) Improvements in and relating to drinking vessels

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20130307

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20140828

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/395 20060101ALI20140822BHEP

Ipc: C07K 16/00 20060101AFI20140822BHEP

Ipc: C07K 16/28 20060101ALI20140822BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20150303